Clinical trials: Recurrent Gastric Adenocarcinoma
Dose Escalation, Safety
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies.
- Conditions
- Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors
- Trial name
- NCT01576666
- Testing
- LDE225, BKM120
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Cancer, Gastric Cancer
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054457
- Testing
- capecitabine, docetaxel
- Where
- 28 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Gastric Cancer, GastroEsophageal Cancer
Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer
This is a Multi-center, Open-label, Randomized Controlled,phase 2 clinical trail of Albumin-bound Paclitaxel Plus SHR-1210 （PD-1 inhibitor）Versus Albumin-bound Paclitaxel as Second-line Treatment in Advanced or Recurrent Gastric…
- Trial name
- NCT04294784
- Testing
- Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound Paclitaxel
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Huazhong University of Science and Technology
Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499291
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, gene expression analysis, laboratory biomarker analysis
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer, Gastric Cancer
Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic or recurrent cancer.
- Conditions
- Breast Cancer, Gastric Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00017537
- Testing
- MVF-HER-2(628-647)-CRL 1005 vaccine
- Sponsor
- University of Alabama at Birmingham
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably.
- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer
- Trial name
- NCT00004895
- Testing
- octreotide acetate
- Where
- United States
- Sponsor
- Northwestern University
Esophageal Cancer, Gastric Cancer
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00020787
- Testing
- G17DT Immunogen, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain Tumors, Gastric Cancer
S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill cancer cells. PURPOSE: This phase I trial is studying two different vaccines to treat patients who have gastric, prostate, or ovarian…
- Conditions
- Brain Tumors, Gastric Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT00023634
- Testing
- KLH, GMCSF
- Where
- 13 sites in United States
- Volunteers
- 14 people
- Sponsor
- SWOG Cancer Research Network
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Gastric Cancer, Cancer of the Stomach
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction…
- Conditions
- Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
- Trial name
- NCT03704077
- Testing
- Relatlimab + Nivolumab, Nivolumab, Paclitaxel
- Where
- 84 sites in United States, Argentina and 12 more
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer
XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer
The aim of this study is to evaluate efficacy and safety of Capecitabine/Cisplatin for gastric cancer patients who relapsed after adjuvant chemotherapy by S-1.
- Trial name
- NCT01412294
- Testing
- Capecitabine, Cisplatin
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Epidemiological and Clinical Research Information Network
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00486356
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum
- Trial name
- NCT00028496
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Stomach Neoplasms, Siewert Type II Adenocarcinoma of Esophagogastric Junction
Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors
The incidence of adenocarcinomas of the esophagogastric junction (AEJ) has increased rapidly during the past decades. By the Siewert classification, the AEJ is the tumor center located 5 cm above the anatomic cardia and 5 cm…
- Conditions
- Stomach Neoplasms, Siewert Type II Adenocarcinoma of Esophagogastric Junction, Recurrence, Siewert Type III Adenocarcinoma of Esophagogastric Junction
- Trial name
- NCT02313688
- Testing
- gastrectomy
- Where
- China
- Volunteers
- 320 people
- Sponsor
- West China Hospital
Esophageal Cancer, Gastric Cancer
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and irinotecan in treating patients…
- Trial name
- NCT00004235
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
The primary objective of this study is to evaluate and compare the efficacy of andecaliximab (GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent gastric or gastroesophageal junction (GEJ)…
- Trial name
- NCT02864381
- Testing
- Andecaliximab, Nivolumab
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 144 people
- Sponsor
- Gilead Sciences
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
This randomized phase II trial studies how well giving irinotecan hydrochloride with or without alvocidib works in treating patients with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT00991952
- Testing
- alvocidib, irinotecan hydrochloride, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)